A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Recruiting in Palo Alto (17 mi)
+9 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
Research Team
PP
Philippe Prokocimer, MD
Principal Investigator
Trius Therapeutics
Eligibility Criteria
Inclusion Criteria
Male or female patients ≥ 18 years of age
Suspected or documented gram-positive infection from baseline Gram stain or culture.
Cellulitis/erysipelas or major cutaneous abscesses at Screening
Treatment Details
Interventions
- TR-701 FA (Other)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: TR-701 FAExperimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Lead Sponsor
Trials
19
Recruited
2,200+
Trius Therapeutics LLC
Lead Sponsor
Trials
19
Recruited
2,200+
Bayer
Industry Sponsor
Trials
2,291
Recruited
25,560,000+
Founded
1863
Headquarters
Leverkusen, Germany
Known For
Pharmaceutical Innovations
Top Products
Aspirin, Aleve, Yaz, Nexavar
Bill Anderson
Bayer
Chief Executive Officer since 2023
BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT
Michael Devoy
Bayer
Chief Medical Officer since 2014
MD, PhD